In this issue:
Vedolizumab for paediatric IBD
Disease activity predictors during pregnancy in women with IBD
Tofacitinib for UC
Early vs. delayed response to vedolizumab/adalimumab: long-term outcomes
FMT for active UC
Risk of developing IBD within and across families
Biologics for budesonide-refractory,-dependent or -intolerant microscopic colitis
Endoscopic postoperative recurrence in CD with early biologic prophylaxis
Safety and efficacy of tofacitinib, stratified by age, in UC
Long-term herpes zoster risk in recipients of tofacitinib for UC
Please login below to download this issue (PDF)